Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Intangibles (2021 - 2024)

Indivior Pharmaceuticals has reported Intangibles over the past 4 years, most recently at $177.0 million for Q4 2024.

  • For Q4 2024, Intangibles fell 24.36% year-over-year to $177.0 million; the TTM value through Dec 2024 reached $177.0 million, down 24.36%, while the annual FY2024 figure was $177.0 million, 24.36% down from the prior year.
  • Intangibles for Q4 2024 was $177.0 million at Indivior Pharmaceuticals, down from $190.0 million in the prior quarter.
  • Over five years, Intangibles peaked at $234.0 million in Q4 2023 and troughed at $70.0 million in Q4 2022.
  • A 4-year average of $179.8 million and a median of $199.0 million in 2023 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: skyrocketed 234.29% in 2023 and later fell 24.36% in 2024.
  • Year by year, Intangibles stood at $82.0 million in 2021, then decreased by 14.63% to $70.0 million in 2022, then skyrocketed by 234.29% to $234.0 million in 2023, then fell by 24.36% to $177.0 million in 2024.
  • Business Quant data shows Intangibles for INDV at $177.0 million in Q4 2024, $190.0 million in Q3 2024, and $218.0 million in Q2 2024.